The Biologic Patent Transparency Act requires drug manufacturers to disclose patents covering their products with the FDA. By increasing transparency, the act forces manufacturers to conform to rules which have proven successful in promoting the development and use of generic drugs.

The bill also targets patent thickets that delay competition without providing meaningful improvements. In addition, the bill will standardize publication of the “Purple Book” and require that the FDA do its part to enhance it in a way that promotes competition.